In constant efforts to improve the outcomes of patients with cancer, scientists frequently
investigate old and commonly prescribed drugs for their potential antineoplastic features.
For statins and metformin, two metabolic agents which are both often prescribed, these
antitumour properties have been suggested in preclinical studies [
[1]
,
[2]
]. Recent phase 3 trials of androgen receptor signalling inhibitors may provide the
opportunity to investigate these putative effects in patients with prostate cancer.
In this issue of the European Journal of Cancer, two complementary retrospective studies report outcomes of the use of statins and
metformin in patients treated in clinical trials with abiraterone acetate plus prednisone/prednisolone or
placebo, and enzalutamide or placebo, respectively.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.J Pharmacol Exp Therapeut. 2011; 336: 496-505
- Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration.Clin Cancer Res. 2018; 24: 5622-5634
- Effects of metformin and statins on outcomes in men with castrate resistant metastatic prostate cancer: secondary analysis of COU-AA-301 and COU-AA-302.Eur J Canc. 2022; 170: 296-304
- Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER.Eur J Canc. 2022; 170: 285-295
- Influence of enzalutamide on cabazitaxel pharmacokinetics: a drug-drug interaction study in metastatic castration-resistant prostate cancer (mCRPC) patients.Clin Cancer Res. 2018; 24: 541-546
- Drug-drug interaction potential of darolutamide: in vitro and clinical studies.Eur J Drug Metab Pharmacokinet. 2019; 44: 747-759
- Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.Clin Cancer Res. 2012; 18: 4433-4440
- Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.Br J Cancer. 2020; 123: 1715-1719
- Environmental and genetic factors affecting transport of imatinib by OATP1A2.Clin Pharmacol Ther. 2011; 89: 816-820
- Drug transporters of platinum-based anticancer agents and their clinical significance.Drug Resist Updates. 2011; 14: 22-34
Article info
Publication history
Published online: May 11, 2022
Accepted:
April 28,
2021
Received:
April 26,
2021
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPEREuropean Journal of CancerVol. 170Open Access
- Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302European Journal of CancerVol. 170Open Access
